Oct 05, 2021 / 12:00PM GMT
Lynne Marie Sullivan - Unity Biotechnology, Inc. - CFO & Head of Corporate Development
Good morning. Thank you for joining the Unity Biotechnology conference call this morning to discuss the 12-week results from our Phase I study of UBX1325. With me on today's call is Robert Bhisitkul, Professor of Ophthalmology and Director of the Retina Fellowship at University of California, San Francisco, a renowned retinal specialist; Anirvan Ghosh, the CEO of Unity Biotechnology; Jamie Dananberg, the Chief Medical Officer of Unity Biotechnology; and myself, Lynne Sullivan, the Chief Financial Officer.
Before turning the call over to Anirvan, I'd like to remind you that during today's call, we'll be making some forward-looking statements, which are subject to risks and uncertainties, including those described in our latest 10-Q filed with the SEC. Actual results may differ materially from today's forward-looking statements, and we do not assume any obligation or intent to update them, except as required by law.
And with that, I'll hand the call over to Anirvan to start the discussion.
UNITY Biotechnology Inc To Discuss The Most Recent UBX1325 Clinical Data Call Transcript
Oct 05, 2021
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers